Pasithea Therapeutics Corp Stock Analysis
KTTAW Stock | USD 0.02 0.0003 1.50% |
Pasithea Therapeutics Corp is overvalued with Real Value of 0.0164 and Hype Value of 0.0194. The main objective of Pasithea Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Pasithea Therapeutics Corp is worth, separate from its market price. There are two main types of Pasithea Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Pasithea Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pasithea Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Pasithea Stock trading window is adjusted to America/New York timezone.
Pasithea |
Pasithea Stock Analysis Notes
The company had not issued any dividends in recent years. Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida. Pasithea Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about Pasithea Therapeutics Corp contact Tiago Marques at 702 514 4174 or learn more at https://www.pasithea.com.Pasithea Therapeutics Investment Alerts
Pasithea Therapeutics is way too risky over 90 days horizon | |
Pasithea Therapeutics has some characteristics of a very speculative penny stock | |
Pasithea Therapeutics appears to be risky and price may revert if volatility continues | |
Pasithea Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the revenue of 486.56 K. Net Loss for the year was (15.51 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Pasithea Therapeutics Corp has accumulated about 568.98 K in cash with (13.43 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Latest headline from news.google.com: Pasithea Therapeutics announces SRC recommended proceeding to cohort 4 - TipRanks |
Pasithea Therapeutics Thematic Classifications
In addition to having Pasithea Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Pasithea Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.94) | (0.90) | |
Return On Capital Employed | (0.68) | (0.71) | |
Return On Assets | (0.61) | (0.64) | |
Return On Equity | (0.68) | (0.65) |
Management Efficiency
The company has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6325) %, meaning that it generated substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.9 in 2024. Return On Capital Employed is likely to drop to -0.71 in 2024. At this time, Pasithea Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 464.2 K in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (8.7 B).Last Reported | Projected for Next Year | ||
Book Value Per Share | 18.54 | 19.45 | |
Tangible Book Value Per Share | 11.25 | 16.43 | |
Enterprise Value Over EBITDA | 0.45 | 0.43 | |
Price Book Value Ratio | 0.40 | 0.38 | |
Enterprise Value Multiple | 0.45 | 0.43 | |
Price Fair Value | 0.40 | 0.38 | |
Enterprise Value | -18.4 M | -17.5 M |
Evaluating the management effectiveness of Pasithea Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Pasithea Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.821 | Return On Assets (0.38) | Return On Equity (0.63) |
Technical Drivers
As of the 25th of November, Pasithea Therapeutics holds the Risk Adjusted Performance of 0.1633, coefficient of variation of 499.3, and Semi Deviation of 16.91. Pasithea Therapeutics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Pasithea Therapeutics information ratio and downside variance to decide if Pasithea Therapeutics is priced some-what accurately, providing market reflects its current price of 0.0203 per share. As Pasithea Therapeutics appears to be a penny stock we also advise to check out its total risk alpha numbers.Pasithea Therapeutics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pasithea Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pasithea Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Pasithea Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pasithea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pasithea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pasithea Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pd Joint Holdings, Llc Series 2016-a over three months ago Disposition of tradable shares by Pd Joint Holdings, Llc Series 2016-a of Pasithea Therapeutics subject to Rule 16b-3 | ||
Abramowitz Israel Maxx over six months ago Discretionary transaction by Abramowitz Israel Maxx of tradable shares of Pasithea Therapeutics subject to Rule 16b-3 | ||
Tiago Marques over six months ago Disposition of tradable shares by Tiago Marques of Pasithea Therapeutics subject to Rule 16b-3 |
Pasithea Therapeutics Predictive Daily Indicators
Pasithea Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pasithea Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | 9.2 T | |||
Rate Of Daily Change | 1.01 | |||
Day Median Price | 0.0203 | |||
Day Typical Price | 0.0203 | |||
Price Action Indicator | 1.0E-4 | |||
Period Momentum Indicator | 3.0E-4 | |||
Relative Strength Index | 51.51 |
Pasithea Therapeutics Forecast Models
Pasithea Therapeutics' time-series forecasting models are one of many Pasithea Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pasithea Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Pasithea Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Pasithea Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pasithea shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pasithea Therapeutics. By using and applying Pasithea Stock analysis, traders can create a robust methodology for identifying Pasithea entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (25.78) | (27.07) | |
Operating Profit Margin | (27.41) | (28.78) | |
Net Loss | (24.15) | (25.36) | |
Gross Profit Margin | 0.69 | 0.73 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Pasithea Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
All Next | Launch Module |
Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.